Dr Terry Snape
DR TERRY SNAPE - QUESTIONS SUBMITTED TO THE INFECTED BLOOD INQUIRY
-
P28 - What are his observations of the email thread?
Did he have contact with Bob Perry regards this matter at the time at all?
Did he discuss the 2019 press enquiry with Bob Perry?
P30 - Who was leading this project as of May 2005?
P45 - re the “tainted blood image” - was this particularly relevant in light of the HIV litigation happening at this time?
What was the reasoning for wanting to “Distance” from the “tainted blood image”?
P54 - What impact, if any, did this have on the manufacture of F8?
P58 - Should there have been an “established coagulation factor research or pilot plant function at BPL”?
P63 - “at the critical time between 1983 and 1987” - Can he explain why he considers 1983 to be the beginning of a “critical time”?
If 1983 was a “critical time”, how would he describe the years before this?
P65 - When he says “designs of their own”, can he provide examples of what they might be?
P66 - Last sentence, from when was this understood?
P67 - Why does he put an end date on this as being 1982/3?
P93 - What does the “CRV” in the batch number stand for? Likewise, HL? NB Some have speculated “CR” stands for Charles Rizza. I don’t know.
P102 - “One might have expected to see a resurgence in usage of single donor cryo from UK donors in 1983-5“ - Can he explain more about why he thinks this and why from 1983?
P104 - “Never commissioned for small pool product manufacture as such” - Why?
Was there any small pool area in the 1970s?
P105 - “BPL was not involved at any time in the recruitment or screening of donors” - The IBI has heard evidence to suggest that fractionators were more alive to dangers of viral risk than others. Should BPL have been involved in this?
P137 - What, if anything, would have stopped someone who had received intravenous immunoglobulin from donating blood?
P147 - He reflects on “unidentified virus” but what about Hepatitis B?
P154 - “In the late 1980s, when we were dealing with the challenges of NANBH and HIV” - This must be an error?
P168 - “to the best of my memory, Behringwerke made no specific claim in respect of inactivation of hepatitis viruses“ - This is incorrect. Claims are made by Behrinwerke in the patent itself. It is repeatedly referred to as “hepatitis-safe”. The purpose of the patent is to describe a process which is “to stabilise them against heat and thus to prevent the transmission of hepatitis when they are administered”.
P184 - “expectation of difficulties in maintaining downstream process integrity from re-infection if in-process pasteurisation were transferred to the ageing manufacturing facility at Elstree, argued against proceeding down the pasteurisation route” - For how long has this been a concern?
P185 - The NIBSC batch release sheets put this date at 12th March 1985, not April 1985.
P189 - “there was no formal recall of unheated factor VIII, either 8CRV or HL” - Why? What consideration was this given?
P202 - Re "THE PREPARATION IS OF HUMAN ORIGIN AND CANNOT BE ASSUMED TO BE FREE OF HEPATITIS VIRUS” Given what he says earlier in his WS, would it not have been more accurate to have said “SHOULD BE ASSUMED TO CONTAIN HEPATITIS VIRUS”.
P216 - So we are to understand that one of the reasons for increasing the level of viral risk was to reduce the cost of quality control?
P238 - “the Medicines Inspectorate defined a cap on BPL output at 15Miu factor VIII per annum“ - Why?
Page 122 - “As a supplier of plasma products, for example Hemofil, Baxter were a competitor” - Can he elaborate on this view that Baxter was a competitor?
Page 163 - In respect of the two recommendations made… “All CTXs (i.e., all clinical trials) for UK blood products should be suspended” & “Clinicians should be educated in minimising the use of blood products”...
Did he agree with those?
Should they have been introduced at an earlier stage?
NON WS QUESTIONS
Can he explain what determined whether or not a batch was sent to NIBSC. It seems as though they sent a batch once every few months but what is the reasoning behind this? How did they choose which batches would be sent and why?
Was there anyone overseeing the new BPL build that had built a new fraction plant before?
If not, would this have been advantageous?
Can he recall any issues around the “method of funding” for the new BPL in respect of increasing timescale?
Was BPL ever approached by Dr Shanbrom to use his SD method?
What R&D was undertaken in respect of attempts to virally inactivate Cryoprecipitate?
Can he assist with what is said here by Bidwell in the first Para re heat treatment?
He is perhaps the only witness we can ask about this, he is mentioned in the last para of the second page here - https://www.dropbox.com/s/0skbu3m1vqzw6g4/IMG_1917.JPG?dl=0
Who managed the document discovery process at BPL during the HIV litigation?
What does he recall about the response of BPL to the development of Speywoods Hyate C Product?
Is there anything he can add more generally about his / BPL’s relationship with Speywood?
